Spanda is pre-commercial. There is no revenue and won't be until the science clears its next bar. What exists today is defensible IP — a thermodynamic simulation engine, a cross-organism finding, an audit methodology, and a falsifiable prediction — plus a clear, staged path to a high-value platform. The plan below is sequenced so each stage is funded by what the previous one proves.
Run the lactate metabolomics validation with a partner lab and publish the results. Deliverable: a wet-lab-anchored result that thermodynamic consistency changes cell-model predictions. This is the credibility that unlocks everything after it.
Offer the detailed-balance audit as a tool/service to the groups who build metabolic and whole-cell models — they have 13–40% wrong-direction reactions and no easy way to find them. Low-cost to deliver, immediately useful, and it seeds the customer relationships for the platform.
A licensable, thermodynamically-consistent whole-cell simulator: perturb-simulate-query virtual cells for antibiotic-target triage, strain design, and mechanism-of-action studies — sold to pharma and biotech R&D as in-silico screening that de-risks the bench. Priced per seat, per organism build, and per co-development programme.
The thermodynamic engine as the substrate other tools build on — multi-organism, spatial, real-time — the conserved-physics layer beneath computational biology, licensed across the field.
Pre-commercial is not pre-substance. The asset already exists; the plan only has to carry it across the validation line.
A working engine + a reproducible cross-organism finding + a falsifiable prediction — not a slide deck.
Every whole-cell and genome-scale modelling group is a potential audit customer; pharma already pays for in-silico R&D.
The decisive next experiment is one metabolomics run, not a wet lab of our own.
No stage assumes the next; each is funded by what the prior one proves.
Every group that builds metabolic or whole-cell models has 13–40% wrong-direction reactions and no easy way to find them. The audit is low-cost to deliver, immediately useful, and it seeds the relationships for the platform.
A thermodynamically-consistent whole-cell simulator for antibiotic-target triage, strain design, and mechanism-of-action studies — sold to pharma and biotech R&D as in-silico screening, priced per seat, per organism build, and per co-development programme.
We will not sell a platform before the science earns it. Today there is defensible IP, a peer-review-stage finding, and a falsifiable prediction — and a clear path that each stage funds the next. That is what we're asking backers to advance, and nothing more.